Company intelligence / Profile preview

SYNAPS Dx

Ownership: Private
Employees: ~20
Development stage: Commercial

Overview

The DISCERN™ test by SYNAPS Dx demonstrates >95% sensitivity and specificity for distinguishing Alzheimer’s disease from other forms of dementia using a minimally invasive skin biopsy. It has been validated against autopsy results and supports more accurate clinical decision-making compared to traditional PET or spinal fluid tests. Clinical utility studies show strong adoption and market receptivity.

Therapeutic areas: Neurology
Modalities: Device (diagnostic test)
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

DISCERN

Commercial

Indications: Alzheimer's disease, Dementia

Partnerships

Semler Scientificcollaborations with providers/researchers using DISCERN™ in trials

Beyond the preview

Go deeper on SYNAPS Dx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYNAPS Dx.

Explore the full profile